Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 in Intermittent Claudication
NCT01731990Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in peripheral artery disease (PAD) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Mean Vessel Wall Area Ratio of 12 Months to Baseline. Started Oct 2012; status: terminated.
02
Drugs
canakinumab
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT01731990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731990.